# ImmuCell Reports 46% Revenue Increase in Third Quarter 2026

- URL: https://stocks.freetheai.org/news/immucell-reports-46-revenue-increase-in-third-quarter-2026-b276ac
- Published: 2026-10-12T20:05:00Z
- Category: earnings; sentiment: bullish; impact: medium
- Symbols: [NASDAQ:ICCC](https://stocks.freetheai.org/symbols/NASDAQ-ICCC)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

ImmuCell Corporation (NASDAQ:ICCC) reported preliminary product sales of $8.0 million for the third quarter of 2026, marking a 46.0% increase compared to the same period in 2025. Domestic sales rose 29.2% to $6.9 million. For the first nine months of 2026, total sales reached $25.6 million, up 27.8% year-over-year. Shares of the animal health company traded down 2.04% at $9.60 following the update.

The quarter's sales growth was broad-based across product lines, led by a 51% surge in Tri-Shield, a 36% gain in Dual-Force, and a 37% increase in the recently introduced functional feed line. Executive leadership credited the performance to an expanded sales team, stronger commercial execution, and consistent manufacturing capabilities that enabled the company to fulfill customer orders reliably. Management noted that prior-year comparisons were impacted by lower third-quarter sales in 2025 due to heavy distributor inventory stocking during the second quarter of that year.

Moving forward, the company plans to end its practice of issuing early preliminary sales updates, aligning its communication schedule with standard regulatory filing practices. Investors will get a detailed view of revenue drivers and overall financial health when the company hosts its third-quarter earnings call on November 13, 2026.

## Key points

- ImmuCell Corporation generated $8.0 million in third-quarter 2026 product sales, representing a 46% increase year-over-year.
- Domestic product sales climbed 29.2% to $6.9 million, while nine-month revenue rose 27.8% to $25.6 million.
- Tri-Shield sales grew 51%, Dual-Force sales increased 36%, and the new functional feed line expanded 37% during the quarter.
- Management announced it will discontinue early preliminary sales releases to align with standard SEC disclosure practices.

## Questions and answers

### What were ImmuCell's product sales in the third quarter of 2026?

ImmuCell reported preliminary total sales of $8.0 million for the third quarter of 2026, representing a 46% increase compared to the third quarter of 2025.

### Why did ImmuCell's product sales increase in Q3 2026?

Growth was driven by an expanded sales team, improved commercial execution, and consistent manufacturing. Product lines Tri-Shield and Dual-Force grew 51% and 36% respectively.

### When will ImmuCell report its full financial results for Q3 2026?

ImmuCell will host a conference call on Friday, November 13, 2026, at 9:00 AM ET to discuss complete quarterly financial metrics.